Martin Heubner

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar B. Kristensen, Isabelle Ray‐Coquard et al. · The Lancet Oncology · 2015 · 207 citations · Full text

Placebo-controlled Phase 3, Medicine, Metronomic Therapy +9

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 157 citations

Medicine, Metronomic Therapy, Gynecology +8

Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy

Bahriye Aktas, Sabine Kasimir‐Bauer, Martin Heubner et al. · International Journal of Gynecological Cancer · 2011 · 108 citations · Full text

Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results

Johannes Grueneisen, Benedikt M. Schaarschmidt, Martin Heubner et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 101 citations

Positron Emission Tomography, Engineering, Cervical Cancer +13

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Advanced Ovarian Cancer, Medicine, Pharmacology +9